Hong Kong SAR

Deutsche Bank has hired Alexandra Yang from Nomura to lead its China sponsor coverage team.

Property developer New World China Land has closed a HK$6.85bn ($880m) loan, attracting nine participants during syndication.

ESR Cayman, a Hong Kong-listed logistics real estate company, is tapping the offshore loan market for a debut $250m borrowing through Standard Chartered.

Global equity capital markets suffered severe hits this week, as governments scrambled to respond to an escalation in the coronavirus pandemic. But amid the mayhem, InnoCare Pharma saw an opportunity to launch its IPO, treating Hong Kong to its largest listing in about two months. Jonathan Breen reports.

These are troubling times. Covid-19 case numbers are jumping every day, more countries are being added to travel ban lists, and the virus outbreak is now officially a pandemic. But some bankers are still finding the positives in all the chaos.

Guangzhou R&F Properties Co has become the latest Hong Kong-listed mainland company planning to convert its domestic shares into H-shares, after China fully opened up the H-share full circulation scheme last November.

Chinese biopharmaceutical firm InnoCare Pharma kicked off bookbuilding for its Hong Kong IPO on Wednesday, securing over half of the deal with cornerstone investors.

Citi has hired industry veteran Loretta Ko as head of Hong Kong financial institutions, within the corporate banking division, according to an internal memo seen by GlobalCapital Asia.

Asia’s IPO markets have been hit hard by the coronavirus epidemic, as travel bans and self-quarantine orders have delayed roadshows and brought deal flow to a near standstill. For the listing markets to survive, issuers, ECM bankers and investors need to adapt rapidly — and put some faith in technology.

China Gas Holdings, a Hong Kong-listed natural gas distributor, doubled the size of its onshore renminbi deal to Rmb1bn on Monday, selling just the second Panda bond linked to combatting woes caused by Covid-19.

China’s Immunotech Biopharm has applied for listing approval in Hong Kong, aiming to raise more than $100m from its IPO, according to a source familiar with the matter.

Apologies millennials, but not everything needs to come with an added perk. Whatever happened to banking being boring?